<sup>18</sup>F-AlF-NOTA-Octreotide Outperforms<sup>68</sup>Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter StudyElin Pauwels, Christophe M. Deroose, Kim Serdons et al.|Journal of Nuclear Medicine|2022Cited by 74
Evaluation of [¹⁸F]AlF-NOTA-octreotide PET/CT in routine clinical use: a retrospective analysis in 288 neuroendocrine tumor patientsHannes Leupe, Christophe M. Deroose, Sophie-Anne De Buyst et al.|European Journal of Nuclear Medicine and Molecular Imaging|2026Cited by 0